Volume 11,Issue 5
Correlation Between Serum Procalcitonin Levels and the Severity of Pediatric Traumatic Brain Injury
Objective: To investigate the correlation between serum procalcitonin (PCT) levels and the severity of pediatric traumatic brain injury (TBI). Methods: Clinical data of 370 pediatric patients with TBI admitted to the Department of Neurosurgery, Jingzhou First People’s Hospital between January 2018 and December 2025 were retrospectively analyzed. Based on the Glasgow Coma Scale (GCS) score, patients were divided into a mild TBI group (GCS 13–15, n = 250) and a moderate-to-severe TBI group (GCS 3–12, n = 120). Serum levels of PCT, C-reactive protein (CRP), white blood cell count (WBC), and neutrophil percentage (N%) within 24 hours of admission were compared between the two groups. The correlation between PCT and GCS score was analyzed. Results: PCT levels in the moderate-to-severe group were significantly higher than those in the mild group [1.82 (0.65, 3.46) vs. 0.06 (0.03, 0.12) μg/L, p < 0.001]. CRP, WBC, and N% were also significantly elevated in the moderate-to-severe group [18.6 (9.4, 34.2) vs. 3.2 (1.5, 6.8) mg/L; 14.7 ± 3.8 vs. 8.3 ± 2.1×109/L; 82.3 ± 6.7% vs. 64.2 ± 5.8%, all p < 0.001]. ROC analysis showed that the area under the curve (AUC) for PCT in discriminating moderate-to-severe TBI was 0.92 (95% CI: 0.88–0.96), significantly outperforming CRP (AUC = 0.85, 95% CI: 0.80–0.90; DeLong test, Z = 2.84, p = 0.004). PCT levels were negatively correlated with GCS scores (r = −0.542, p < 0.001). Conclusions: Serum PCT levels are negatively correlated with GCS scores in children with TBI, with higher PCT levels indicating greater injury severity. PCT demonstrates excellent diagnostic performance for discriminating moderate-to-severe TBI (AUC = 0.92), superior to CRP (AUC = 0.85), and may serve as a valuable adjunctive biomarker for assessing injury severity in this population.
[1] Mućka S, Jakubiak G, Pawlas N, et al., 2025, Procalcitonin: Infection or Maybe Something More? Noninfectious Causes of Increased Serum Procalcitonin Concentration: Updated Knowledge. Life (Basel), 15(3): 446.
[2] Hamzelou S, Nourmohammadpour P, Fatima F, et al., 2024, Procalcitonin Serum Level in Patients with Pemphigus Vulgaris: Can It Be Used as an Inflammatory Biomarker? Archives of Dermatological Research, 316(10): 725.
[3] Brabenec L, Müller M, Hellenthal K, et al., 2022, Targeting Procalcitonin Protects Vascular Barrier Integrity. American Journal of Respiratory and Critical Care Medicine, 206(4): 488–500.
[4] Maves R, Enwezor C, 2022, Uses of Procalcitonin as a Biomarker in Critical Care Medicine. Infectious Disease Clinics of North America, 36(4): 897–909.
[5] Ye J, Hu X, Wang Z, et al., 2023, The Role of mtDAMPs in the Trauma Induced Systemic Inflammatory Response Syndrome. Frontiers in Immunology, 14: 1164187.
[6] Baral H, Kaundal R, 2025, Novel Insights into Neuroinflammatory Mechanisms in Traumatic Brain Injury: Focus on Pattern Recognition Receptors as Therapeutic Targets. Cytokine & Growth Factor Reviews, 83: 18–34.
[7] Wang R, Hua Y, He M, et al., 2022, Prognostic Value of Serum Procalcitonin Based Model in Moderate to Severe Traumatic Brain Injury Patients. Journal of Inflammation Research, 15: 4981–4993.
[8] Kirkham F, Newton C, 2003, Assessment of Coma in Children. Archives of Disease in Childhood, 88(4): 362–364.
[9] Tamás A, Tóth D, Pham D, et al., 2021, Changes of Pituitary Adenylate Cyclase Activating Polypeptide (PACAP) Level in Polytrauma Patients in the Early Post Traumatic Period. Peptides, 146: 170645.
[10] Albuali W, 2023, Procalcitonin Biomarker for Sepsis in Postoperative Pediatric Trauma Patients: Three Years of Experience from a Tertiary University Hospital. Current Pediatric Reviews, 19(3): 296–303.